Literature DB >> 31646816

Radiofrequency ablation of primary non-small cell lung cancer: A retrospective study on 108 patients.

Yang Gao1, Jun Chen, Jin Zhang, Lei Sun, Yiping Zhuang.   

Abstract

PURPOSE: To retrospectively analyze the factors influencing response, local progression, local progression-free survival (LPFS), and overall survival (OS) in patients with primary non-small cell lung cancer (NSCLC) after computed tomography (CT)-guided radiofrequency ablation (RFA).
METHODS: From August 2012 to October 2017, 108 lesions of 108 patients who had undergone CT-guided RFA were analyzed in this study. Patients were followed after RFA continuously. Meanwhile, technical success rate, incomplete ablation rate, local progression, LPFS and OS were assessed.
RESULTS: In all patients, 100% technical success rate was achieved. Incomplete ablation rate was 9.26% (10 of 108). Maximum diameter of lesions was associated with incomplete ablation. Maximum diameter of lesions, clinical stage, solitary lesion in the lung and treatments after initial RFA were significantly related to LPFS. Maximum diameter of lesions clinical stage, solitary lesion in the lung, histologic types and treatments after initial RFA were significantly related to OS.
CONCLUSIONS: Maximum diameter of lesions ≤3cm, early clinical stage, solitary lesion in the lung and RFA combined with cisplatin and carboplatin chemotherapy and/or tyrosine kinase inhibitors (TKI) all were positive factors of local efficacy and survival after RFA of primary NSCLC.

Entities:  

Mesh:

Year:  2019        PMID: 31646816

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  4 in total

Review 1.  RFA of primary and metastatic lung tumors: long-term results.

Authors:  Stefano Giusto Picchi; Giulia Lassandro; Andrea Bianco; Andrea Coppola; Anna Maria Ierardi; Umberto G Rossi; Francesco Lassandro
Journal:  Med Oncol       Date:  2020-03-27       Impact factor: 3.064

Review 2.  Advances and controversies in the management of early stage non-small cell lung cancer.

Authors:  Angel Cilleruelo-Ramos; Esther Cladellas-Gutiérrez; Carolina de la Pinta; Laura Quintana-Cortés; Paloma Sosa-Fajardo; Felipe Couñago; Xabier Mielgo-Rubio; Juan Carlos Trujillo-Reyes
Journal:  World J Clin Oncol       Date:  2021-12-24

Review 3.  Current Management of Oligometastatic Lung Cancer and Future Perspectives: Results of Thermal Ablation as a Local Ablative Therapy.

Authors:  Mario Ghosn; Stephen B Solomon
Journal:  Cancers (Basel)       Date:  2021-10-16       Impact factor: 6.639

4.  Heat-activated nanomedicine formulation improves the anticancer potential of the HSP90 inhibitor luminespib in vitro.

Authors:  Brittany Epp-Ducharme; Michael Dunne; Linyu Fan; James C Evans; Lubabah Ahmed; Pauric Bannigan; Christine Allen
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.